| Production of 177Lu for Targeted Radionuclide Therapy: Available Options A Dash, MRA Pillai, FF Knapp Nuclear medicine and molecular imaging 49, 85-107, 2015 | 356 | 2015 |
| Evolution of Tc-99m in diagnostic radiopharmaceuticals S Banerjee, MRA Pillai, N Ramamoorthy Seminars in nuclear medicine 31 (4), 260-277, 2001 | 338 | 2001 |
| Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications S Banerjee, MRA Pillai, FF Knapp Chemical reviews 115 (8), 2934-2974, 2015 | 313 | 2015 |
| Production logistics of 177Lu for radionuclide therapy MRA Pillai, S Chakraborty, T Das, M Venkatesh, N Ramamoorthy Applied radiation and isotopes 59 (2-3), 109-118, 2003 | 234 | 2003 |
| Fluorine-18 radiopharmaceuticals beyond [18F] FDG for use in oncology and neurosciences HH Coenen, PH Elsinga, R Iwata, MR Kilbourn, MRA Pillai, MGR Rajan, ... Nuclear medicine and biology 37 (7), 727-740, 2010 | 175 | 2010 |
| Sustained availability of 99mTc: possible paths forward MRA Pillai, A Dash, FFR Knapp Journal of Nuclear Medicine 54 (2), 313-323, 2013 | 157 | 2013 |
| Peptide receptor radionuclide therapy: an overview A Dash, S Chakraborty, MRA Pillai, FF Knapp Jr Cancer Biotherapy and Radiopharmaceuticals 30 (2), 47-71, 2015 | 144 | 2015 |
| Targeted radionuclide therapy-an overview A Dash, F F Russ Knapp, M Ra Pillai Current radiopharmaceuticals 6 (3), 152-180, 2013 | 131 | 2013 |
| Options to meet the future global demand of radionuclides for radionuclide therapy T Das, MRA Pillai Nuclear medicine and biology 40 (1), 23-32, 2013 | 120 | 2013 |
| 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma A Sasikumar, A Joy, R Nanabala, MRA Pillai, B Thomas, KR Vikraman European journal of nuclear medicine and molecular imaging 43, 795-796, 2016 | 113 | 2016 |
| Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy R Chakravarty, U Pandey, RB Manolkar, A Dash, M Venkatesh, ... Nuclear medicine and biology 35 (2), 245-253, 2008 | 113 | 2008 |
| 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis S Chakraborty, T Das, S Banerjee, L Balogh, PR Chaudhari, HD Sarma, ... Cancer biotherapy & radiopharmaceuticals 23 (2), 202-213, 2008 | 111 | 2008 |
| 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation T Das, S Chakraborty, PR Unni, S Banerjee, G Samuel, HD Sarma, ... Applied Radiation and Isotopes 57 (2), 177-184, 2002 | 108 | 2002 |
| Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis A Sasikumar, A Joy, MRA Pillai, R Nanabala, PG Jayaprakash, ... Clinical Nuclear Medicine 42 (1), e41-e48, 2017 | 107 | 2017 |
| 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation S Chakraborty, T Das, PR Unni, HD Sarma, G Samuel, S Banerjee, ... Nuclear medicine communications 23 (1), 67-74, 2002 | 107 | 2002 |
| 99Mo/99mTc separation: An assessment of technology options A Dash, FFR Knapp Jr, MRA Pillai Nuclear medicine and biology 40 (2), 167-176, 2013 | 103 | 2013 |
| Rhenium-188: availability from the 188W/188Re generator and status of current applications M RA Pillai, A Dash, F F Knapp Current radiopharmaceuticals 5 (3), 228-243, 2012 | 101 | 2012 |
| Availability of yttrium-90 from strontium-90: a nuclear medicine perspective R Chakravarty, A Dash Cancer Biotherapy and Radiopharmaceuticals 27 (10), 621-641, 2012 | 97 | 2012 |
| Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer MRA Pillai, R Nanabala, A Joy, A Sasikumar, FFR Knapp Nuclear medicine and biology 43 (11), 692-720, 2016 | 93 | 2016 |
| 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation T Das, S Chakraborty, HD Sarma, P Tandon, S Banerjee, M Venkatesh, ... Nuclear medicine and biology 36 (5), 561-568, 2009 | 83 | 2009 |
Haladhar Dev SarmaScientific Officer, Bhabha Atomic Research Centre, IndiaVerified email at barc.gov.in
